All In Biotech

NDA 212209 · Azurity

Vivimusta

Bendamustine Hydrochloride · Intravenous

Last checked: Nov 21, 2026Latest source record: Feb 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 7, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

426

81 Phase 3, 51 recruiting

FAERS reports

7,958

7,618 serious, 1,556 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

VIVIMUSTA is an alkylating drug indicated for treatment of patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) VIVIMUSTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) VIVIMUSTA is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Mechanism: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 7, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • VIVIMUSTA · BENDAMUSTINE HYDROCHLORIDE 100MG/4ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use995
  • pyrexia555
  • disease progression510
  • covid-19406
  • product use in unapproved indication401
  • drug ineffective392
  • febrile neutropenia366
  • malignant neoplasm progression362
  • neutrophil count decreased354
  • neutropenia345
  • platelet count decreased342
  • pneumonia342

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20093
20102
201115
2012129
201346
2014267
2015423
2016435
2017400
2018594
2019583
2020607
2021731
20221,445
20231,011
2024735
2025299
2026232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Vivimusta (Bendamustine HCL) · HCPCS J9056

2024 spending

$11.7M

Beneficiaries

375

2,350 claims

Per beneficiary

$31,265

2024 ASP limit $30.32 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$2,405,725
2024$11,724,323

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 385 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.